ALXO - Zymeworks gets dosing underway in early-stage zanidatamab breast cancer study

Zymeworks (NYSE:ZYME) and ALX Oncology Holdings (NASDAQ:ALXO) announce the first patient has been dosed in the early-stage trial of zanidatamab in certain patients with breast cancer. The trial is designed to evaluate the safety and efficacy of zanidatamab in combination with evorpacept in patients with advanced HER2-positive breast cancer, HER2-low breast cancer and additional non-breast HER2-expressing solid tumors. Zanidatamab is designed to have multiple mechanisms of action, including immune clearance of HER2?expressing tumor cells by macrophages through antibody-dependent cellular phagocytosis (ADCP). Zymeworks had posted data indicating that zanidatamab showed promising response rate and durability in esophageal cancer, last month.

For further details see:

Zymeworks gets dosing underway in early-stage zanidatamab breast cancer study